Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study.

[1]  Xin Sun,et al.  Effect of adjuvant chemotherapy on the survival outcomes of elderly breast cancer: A retrospective cohort study based on SEER database , 2022, Journal of evidence-based medicine.

[2]  Guangyu Liu,et al.  Treatment and survival outcomes in older women with primary breast cancer: A retrospective propensity score-matched analysis , 2022, Breast.

[3]  G. Boriani,et al.  2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). , 2022, European heart journal.

[4]  T. Gathani,et al.  Understanding breast cancer as a global health concern , 2021, The British journal of radiology.

[5]  G. Bao,et al.  Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study , 2021, BMC Cancer.

[6]  P. Villagrasa,et al.  Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study , 2021, Frontiers in Oncology.

[7]  T. Marwick,et al.  Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. , 2020, Journal of the American College of Cardiology.

[8]  J. Moslehi,et al.  Age-Related Considerations in Cardio-Oncology , 2020, Journal of cardiovascular pharmacology and therapeutics.

[9]  F. Macedo,et al.  Acute toxicity and tolerability of anthracycline-based chemotherapy regimens in older versus younger patients with breast cancer: real-world data , 2020, Supportive Care in Cancer.

[10]  J. Herrmann.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia , 2020, Nature Reviews Cardiology.

[11]  Tianli Hui,et al.  Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052) , 2019, Scientific Reports.

[12]  M. Totzeck,et al.  Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta‐analysis , 2019, European journal of heart failure.

[13]  E. Oikonomou,et al.  Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. , 2019, JAMA cardiology.

[14]  O. Goletti,et al.  Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients. , 2017, Breast.

[15]  N. Pondé,et al.  Adjuvant chemotherapy in elderly patients with breast cancer: key challenges , 2016, Expert review of anticancer therapy.

[16]  J. Baselga,et al.  Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study , 2015, Breast Cancer Research and Treatment.

[17]  S. Barni,et al.  Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  S. Rivankar.  An overview of doxorubicin formulations in cancer therapy. , 2014, Journal of cancer research and therapeutics.

[19]  Delong Liu,et al.  Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis , 2012, Experimental Hematology & Oncology.

[20]  D. Budman,et al.  Adjuvant Chemotherapy for Early Breast Cancer in the Elderly , 2009, Current treatment options in oncology.

[21]  T. Safra.  Cardiac safety of liposomal anthracyclines. , 2003, The oncologist.

[22]  H. Gogas,et al.  Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. A’Hern.  Sample size tables for exact single‐stage phase II designs , 2001, Statistics in medicine.

[24]  M. Extermann,et al.  Management of cancer in the older person: a practical approach. , 2000, The oncologist.